# US 2015/0147315 A1 · Compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147315 A1
- Document ID: US20150147315A1
- Status: Published application
- Kind: A1
- Application number: 14/397,293
- Filed: 2013-04-29
- Published: 2015-05-28
- Earliest claimed: 2012-04-27
- Assignees: Shandong Xinchuang Biotechnology Co., Ltd.
- Applicants: Griffith University
- Inventors: Ming Wei
- Web page: https://patentgrep.com/patent/US20150147315A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- C12N 1/36: Adaptation or attenuation of cells
- A61K 2039/505: {comprising antibodies}
- C12R 2001/145: Clostridium
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present invention relates to a derivative bacterial strain of an avirulent, non-pathogenic Clostridium ghonii that is capable of arresting the growth of, regressing or destroying one or more solid tumours. The present invention further relates to a composition comprising the derivative bacterial strain for targeted lysis of solid tumours. The present invention further relates to methods of producing derivative strains of C. ghonii by serial culturing in tumor bearing animals.

## Claims

### Claim at position 1

1-63. (canceled)

### Claim 64

A bacterial strain derived from an avirulent, non-pathogenic strain of Clostridium ghonii, wherein the derived bacterial strain is capable of arresting growth of, regressing or destroying a solid tumour.

### Claim 65 (depends on 64)

The strain of claim 64, wherein said strain oncolyses cells contained within the microenvironment of the tumour.

### Claim 66 (depends on 64)

The strain of claim 64, wherein the strain lyses about 20% to about 90% of cells within the microenvironment of the tumour.

### Claim 67 (depends on 64)

The strain of claim 64, wherein the strain lyses about 20% to about 70% of cells within the microenvironment of the tumour.

### Claim 68 (depends on 64)

The strain of claim 64, wherein the strain lyses about 20% to about 40% of cells within the microenvironment of the tumour.

### Claim 69 (depends on 64)

The strain of claim 64, wherein the strain lyses about 20% to about 35% of cells within the microenvironment of the tumour.

### Claim 70 (depends on 64)

The strain of claim 64, wherein the strain lyses about 25% to about 35% of cells within the microenvironment of the tumour.

### Claim 71 (depends on 64)

The strain of claim 64, wherein the strain causes less toxicity than a reference clostridial strain.

### Claim 72 (depends on 64)

The strain of claim 64, wherein the avirulent, non-pathogenic strain of Clostridium ghonii is selected from the group consisting of ATCC Accession No. 25757, BCRC Accession No. 14548, CCUG Accession No. 9282, DSM Accession No. 15049, NCIMB Accession No. 10636, PEV, Prevot PEV, VPI Accession No. 4897 and VTT Accession No. E-042451.

### Claim 73 (depends on 64)

The strain of claim 64, wherein the strain is selected from the group consisting of MW-DCG_LCv1, MW-DCG_LCv2, MW-DCG_LCv3, MW-DCG_LCv4, MW-DCG_LCv5, MW-DCG_LCv6, MW-DCG_LCv7, MW-DCG_LCv8, MW-DCG_LCv9, MW-DCG_LCv10, MW-DCG_LCv11, MW-DCG_LCv12, MW-DCG_LCv13, MW-DCG_LCv14, MW-DCG_LCv15, MW-DCG_LCv16, MW-DCG_LCv17, MW-DCG_LCv18, MW-DCG_LCv19, MW-DCG_LCv20, MW-DCG_LCv21, MW-DCG_LCv22, MW-DCG_LCv23, MW-DCG_LCv24, MW-DCG_LCv25, MW-DCG_LCv26, MW-DCG_CCv13, MW-DCG_CCv14, MW-DCG_CCv15, MW-DCG_CCv16, MW-DCG_CCv17, MW-DCG_HNCv13, MW-DCG_HNCv14, MW-DCG_HNCv15, MW-DCG_HNCv16, MW-DCG_HNCv17 and MW-DCG_HNCv18.

### Claim 74 (depends on 73)

The strain of claim 73, wherein the strain is selected from the group consisting of MW-DCG_LCv1, MW-DCG_LCv2, MW-DCG_LCv3, MW-DCG_LCv4, MW-DCG_LCv5, MW-DCG_LCv6, MW-DCG_LCv7, MW-DCG_LCv8, MW-DCG_LCv9, MW-DCG_LCv10, MW-DCG_LCv11, MW-DCG_LCv12, DCG_HNCv13, MW-DCG_HNCv14, MW-DCG_HNCv15, MW-DCG_HNCv16, MW-DCG_HNCv17 and MW-DCG_HNCv18 wherein the strain has specificity for and are therapeutically effective against solid tumours of head and neck cancer.

### Claim 75 (depends on 74)

The strain of claim 74, wherein the strain is MW-DCG_HNCv18 as represented by Accession Number V12/001485.

### Claim 76 (depends on 73)

The strain of claim 73, wherein the strain is selected from the group consisting of MW-DCG_LCv1, MW-DCG_LCv2, MW-DCG_LCv3, MW-DCG_LCv4, MW-DCG_LCv5, MW-DCG_LCv6, MW-DCG_LCv7, MW-DCG_LCv8, MW-DCG_LCv9, MW-DCG_LCv10, MW-DCG_LCv11, MW-DCG_LCv12, MW-DCG_CCv13, MW-DCG_CCv14, MW-DCG_CCv15, MW-DCG_CCv16 and MW-DCG_CCv17 wherein the strain has specificity for and are therapeutically effective against solid tumours of colon cancer.

### Claim 77 (depends on 76)

The strain of claim 76, wherein the strain is MW-DCG_CCv17 as represented by Accession Number V12/001487.

### Claim 78 (depends on 73)

The strain of claim 73, wherein the strain is selected from the group consisting of MW-DCG_LCv1, MW-DCG_LCv2, MW-DCG_LCv3, MW-DCG_LCv4, MW-DCG_LCv5, MW-DCG_LCv6, MW-DCG_LCv7, MW-DCG_LCv8, MW-DCG_LCv9, MW-DCG_LCv10, MW-DCG_LCv11, MW-DCG_LCv12, MW-DCG_LCv13, MW-DCG_LCv14, MW-DCG_LCv15, MW-DCG_LCv16, MW-DCG_LCv17, MW-DCG_LCv18, MW-DCG_LCv19, MW-DCG_LCv20, MW-DCG_LCv21, MW-DCG_LCv22, MW-DCG_LCv23, MW-DCG_LCv24, MW-DCG_LCv25 and MW-DCG_LCv26 wherein the strain has specificity for and are therapeutically effective against solid tumours of lung cancer.

### Claim 79 (depends on 78)

The strain of claim 78, wherein the strain is MW-DCG_LCv26 as represented by Accession Number V12/001486.

### Claim 80 (depends on 64)

A clostridial spore of the strain of claim 64.

### Claim 81 (depends on 80)

The clostridial spore of claim 80 in combination with a physiologically acceptable carrier and/or excipient.

### Claim 82 (depends on 80)

A method of arresting the growth of, regressing or destroying one or more solid malignant tumours in a subject, wherein the method comprises administration of a therapeutically effective amount of one or more clostridial spores according to claim 80 to said subject in need thereof.

### Claim 83 (depends on 80)

Use of one or more clostridial spores according to claim 80 to arrest the growth of, regress, or destroy one or more solid tumours in a subject, wherein a therapeutically effective amount of said one or more spores is administered to said subject in need thereof.

### Claim 84 (depends on 80)

A method of treating one or more solid malignant tumours in a subject, wherein growth arrest of the tumour, tumour regression or tumour destruction is indicative of the treatment, wherein the method comprises administration of
(1) a therapeutically effective amount of one or more clostridial spores according to claim 80 and
(2) a therapeutically effective amount of an anti-cancer agent to said subject.

### Claim 85 (depends on 81)

Use of one or more clostridial spores according to claim 81 and an anti-cancer agent in a combination therapy for treating one or more solid malignant tumours in a subject, wherein growth arrest of one or more of the tumours, tumour regression or tumour destruction is indicative of the treatment, wherein (1) a therapeutically effective amount of said one or more clostridial spores and (2) a therapeutically effective amount of said anti-cancer agent is administered to said subject in need thereof.
